Filter by Event: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018

Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design.

Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design. Lead author: MD Huband, presented at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2492

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2432

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program.

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2434

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2431

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China.

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1662

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum. Lead author: HS Sader presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1817

Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents.

Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1805

In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results.

In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results. Lead author: MD Huband, presented in European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1822

Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017).

Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1807

Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa.

Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1661